An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy

Tsuyoshi Yoshizawa; Kenya Yamaguchi; Nozomu Kawata; Hitomi Ryuzaki; Masahiro Ogawa; Daisuke Obinata; Junichi Mochida; Satoru Takahashi

doi:10.2169/internalmedicine.3302-19

CASE REPORTS

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy

Tsuyoshi Yoshizawa, Kenya Yamaguchi, Nozomu Kawata, Hitomi Ryuzaki, Masahiro Ogawa, Daisuke Obinata, Junichi Mochida, Satoru Takahashi

Author information

Keywords: ERG gene, fluorescence in situ hybridization, metastatic castration-resistant prostate cancer, abiraterone, durable complete response

JOURNAL OPEN ACCESS

2020 Volume 59 Issue 3 Pages 395-399

DOI https://doi.org/10.2169/internalmedicine.3302-19

Browse “Advance online publication” version

Details

Abstract

We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.

Corresponding author

Register with J-STAGE for free!